| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Scirrhous carcinomas carry an extreme poor prognosis. FGFR-2/K-samII, a tyrosine kinase growth factor receptor, is overexpressed on scirrhous gastric cancer cells. Transforming growth factor-β (TGFβ) signals are closely associated with the distant metastases of gastric cancer. The aim of this study is to clarify the effect of a FGFR-2/K-samII inhibitor, Ki23057, or a TGFβ receptor (TβR) inhibitor, Ki26894, in combination with anticancer drugs TS1 (a 5-fluorouracil analog), on the development of scirrhous gastric cancer. The combined administration of TS1and Ki23057 decreases orthotopic tumors as well as LN metastasis more effectively than TS1 alone. The Ki26894 plus TS1 administration group also significantly suppressed tumor growth and decreased LN metastasis more effectively than either alone. These findings suggested that the combined treatment with 5-FU and FGFR-2 phosphorylation inhibitor or TβR inhibitor produced synergistic anti-tumor effects, and appears therapeutically promising in scirrhous gastric carcinoma treatment.
|
